{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:00:09Z","timestamp":1790470809947,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.heliyon.2023.e16813","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T13:19:33Z","timestamp":1686143973000},"page":"e16813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-0018","authenticated-orcid":false,"given":"Rahul Soloman","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-0999","authenticated-orcid":false,"given":"Gladson David","family":"Masih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitika","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Raj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Suroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phulen","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Prajapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusuya","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-1180","authenticated-orcid":false,"given":"Bikash","family":"Medhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e16813_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e16813_bib2","volume":"vols. 6\u20139","author":"Director-General","year":"2020"},{"key":"10.1016\/j.heliyon.2023.e16813_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2023.e16813_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ijp.IJP_310_20","article-title":"COVID-19 pandemic: a review based on current evidence","volume":"52","author":"Mahalmani","year":"2020","journal-title":"Indian J. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2023.e16813_bib6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","article-title":"Subunit vaccines against emerging pathogenic human coronaviruses","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib7","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2023.e16813_bib8","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12250-020-00252-z","article-title":"A comprehensive review of animal models for coronaviruses: SARS-CoV-2, SARS-CoV, and MERS-CoV","volume":"35","author":"Singh","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.heliyon.2023.e16813_bib10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14760584.2018.1506702","article-title":"Prospects for a MERS-CoV spike vaccine","volume":"17","author":"Zhou","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.heliyon.2023.e16813_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.7150\/thno.48342","article-title":"Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials","volume":"11","author":"Han","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.heliyon.2023.e16813_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104820","article-title":"Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2","volume":"179","author":"Tai","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2023.e16813_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40121-020-00300-x","article-title":"Vaccines for SARS-CoV-2: lessons from other coronavirus strains","volume":"9","author":"Padron-Regalado","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.heliyon.2023.e16813_bib14","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1128\/JVI.02711-15","article-title":"Signatures in simian immunodeficiency virus SIVsmE660 envelope gp120 are associated with mucosal transmission but not vaccination breakthrough in rhesus macaques","volume":"90","author":"Smith","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib15","first-page":"1","article-title":"What is a quasispecies? Historical origins and current scope","volume":"392","author":"Domingo","year":"2016","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"80","key":"10.1016\/j.heliyon.2023.e16813_bib16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1126\/science.7041255","article-title":"Rapid evolution of RNA genomes","volume":"216","author":"Holland","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e16813_bib17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1128\/br.30.3.517-529.1966","article-title":"Effect of route of inoculation on experimental respiratory viral disease in volunteers and evidence for airborne transmission","volume":"30","author":"Couch","year":"1966","journal-title":"Bacteriol. Rev."},{"key":"10.1016\/j.heliyon.2023.e16813_bib18","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1128\/JVI.03235-14","article-title":"Conserved molecular signatures in gp120 are associated with the genetic bottleneck during simian immunodeficiency virus (SIV), SIV-human immunodeficiency virus (SHIV), and HIV type 1 (HIV-1) transmission","volume":"89","author":"Gonzalez","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.immuni.2015.10.014","article-title":"Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design","volume":"43","author":"Andrabi","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2023.e16813_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091591","article-title":"Structure-based reverse vaccinology failed in the case of HIV because it disregarded accepted immunological theory","volume":"17","author":"Van Regenmortel","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2023.e16813_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","article-title":"Broadly neutralizing antibodies to HIV and their role in vaccine design","volume":"34","author":"Burton","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12509","article-title":"Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development","volume":"275","author":"Bonsignori","year":"2017","journal-title":"Immunol. Rev."},{"issue":"80","key":"10.1016\/j.heliyon.2023.e16813_bib23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.aan0662","article-title":"Developing an HIV vaccine","volume":"355","author":"Haynes","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e16813_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature07352","article-title":"Challenges in the development of an HIV-1 vaccine","volume":"455","author":"Barouch","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e16813_bib25","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMc1609015","article-title":"Zika virus and the guillain\u2013barr\u00e9 syndrome \u2014 case series from seven countries","volume":"375","author":"dos Santos","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"80","key":"10.1016\/j.heliyon.2023.e16813_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","volume":"356","author":"Bardina","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e16813_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e16813_bib28","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMoa1711038","article-title":"Zika virus shedding in semen of symptomatic infected men","volume":"378","author":"Mead","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"80","key":"10.1016\/j.heliyon.2023.e16813_bib29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1126\/science.1097211","article-title":"Mapping the antigenic and genetic evolution of influenza virus","volume":"305","author":"Smith","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e16813_bib30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7774\/cevr.2014.3.1.12","article-title":"New vaccines against influenza virus","volume":"3","author":"Lee","year":"2014","journal-title":"Clin. Exp. Vaccine Res."},{"key":"10.1016\/j.heliyon.2023.e16813_bib31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.chom.2015.02.012","article-title":"Influenza vaccines: challenges and solutions","volume":"17","author":"Houser","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.heliyon.2023.e16813_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.chom.2010.05.009","article-title":"Influenza virus evolution, host adaptation, and pandemic formation","volume":"7","author":"Taubenberger","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.heliyon.2023.e16813_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coi.2014.03.008","article-title":"Immunosenescence: influenza vaccination and the elderly","volume":"29","author":"Haq","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib34","doi-asserted-by":"crossref","first-page":"200ra114","DOI":"10.1126\/scitranslmed.3006366","article-title":"Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease","volume":"5","author":"Khurana","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2023.e16813_bib35","doi-asserted-by":"crossref","first-page":"f794","DOI":"10.1136\/bmj.f794","article-title":"Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine: retrospective analysis","volume":"346","author":"Miller","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2023.e16813_bib36","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","article-title":"Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis","volume":"378","author":"Nair","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e16813_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-017-4032-2","article-title":"The impact of a vaccine scare on parental views, trust and information needs: a qualitative study in Sydney, Australia","volume":"17","author":"King","year":"2017","journal-title":"BMC Publ. Health"},{"key":"10.1016\/j.heliyon.2023.e16813_bib38","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2023.e16813_bib39","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.4049\/jimmunol.176.5.2825","article-title":"The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection","volume":"176","author":"Huang","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib40","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/088282403763635465","article-title":"Antibody-dependent enhancement of virus infection and disease","volume":"16","author":"Tirado","year":"2003","journal-title":"Viral Immunol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/icb.1964.44","article-title":"Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls","volume":"42","author":"Hawkes","year":"1964","journal-title":"Aust. J. Exp. Biol. Med. Sci."},{"key":"10.1016\/j.heliyon.2023.e16813_bib43","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1128\/jvi.69.4.2393-2400.1995","article-title":"Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection","volume":"69","author":"Lund","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib45","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.4049\/jimmunol.176.5.2825","article-title":"The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection","volume":"176","author":"Huang","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7239347","article-title":"Cross-reaction, enhancement, and neutralization activity of dengue virus antibodies against zika virus: a study in the mexican population","volume":"2019","author":"Montecillo-Aguado","year":"2019","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.heliyon.2023.e16813_bib47","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cmi.2017.11.004","article-title":"Adverse birth outcomes associated with Zika virus exposure during pregnancy in S\u00e3o Jos\u00e9 do Rio Preto, Brazil","volume":"24","author":"Nogueira","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.heliyon.2023.e16813_bib48","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1111\/bph.15143","article-title":"Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology","volume":"177","author":"Cleary","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.antiviral.2015.08.013","article-title":"Animal models for studying dengue pathogenesis and therapy","volume":"123","author":"Chan","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.heliyon.2023.e16813_bib50","article-title":"Tree shrew as a new animal model for the study of dengue virus","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib51","series-title":"Ervebo | Fda","first-page":"1","author":"Food and Drug Administration (Fda)","year":"2020"},{"key":"10.1016\/j.heliyon.2023.e16813_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008859","article-title":"Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations","volume":"6","author":"Thorson","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.heliyon.2023.e16813_bib53","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/infdis\/jiv532","article-title":"Stability of a vesicular stomatitis virus-vectored Ebola vaccine","volume":"213","author":"Arnemo","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2023.e16813_bib54","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1080\/22221751.2021.1969868","article-title":"Host-dependent editing of SARS-CoV-2 in COVID-19 patients","volume":"10","author":"Gregori","year":"2021","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.heliyon.2023.e16813_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104585","article-title":"SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies","volume":"131","author":"Karamitros","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib56","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New\u2010onset autoimmune phenomena post\u2010COVID\u201019 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.heliyon.2023.e16813_bib57","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10067-022-06149-4","article-title":"Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune\/inflammatory syndrome expand?","volume":"41","author":"Jara","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.smim.2018.10.010","article-title":"Vaccination in the elderly: the challenge of immune changes with aging","volume":"40","author":"Ciabattini","year":"2018","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib59","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.jaad.2021.01.047","article-title":"An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology","volume":"84","author":"Gresham","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib60","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2023.e16813_bib61","series-title":"COVAX: Working for Global Equitable Access to COVID-19 Vaccines","first-page":"1","author":"Organization","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00263-2","article-title":"Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities","volume":"21","author":"Dal-R\u00e9","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2023.e16813_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000003","article-title":"Why are RNA virus mutation rates so damn high?","volume":"16","author":"Duffy","year":"2018","journal-title":"PLoS Biol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib64","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1371\/journal.ppat.0030201","article-title":"A single mutation in Chikungunya virus affects vector specificity and epidemic potential","volume":"3","author":"Tsetsarkin","year":"2007","journal-title":"PLoS Pathog."},{"issue":"80","key":"10.1016\/j.heliyon.2023.e16813_bib65","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza A\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e16813_bib66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/infdis\/jiy409","article-title":"Influenza A(H7N9) virus evolution: which genetic mutations are antigenically important?","volume":"219","author":"Petrie","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2023.e16813_bib67","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2023.e16813_bib68","first-page":"331","article-title":"Impact of circulating SARS-CoV-2 mutant G614 on the COVID-19 pandemic, Iran","volume":"14","author":"Ahmadpour","year":"2020","journal-title":"J. Kidney Dis."},{"key":"10.1016\/j.heliyon.2023.e16813_bib69","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2023.e16813_bib70","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.chom.2021.02.020","article-title":"The variant gambit: COVID-19's next move","volume":"29","author":"Plante","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.heliyon.2023.e16813_bib71","volume":"vol. 1","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib72","first-page":"1","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron, Emerg","volume":"11","author":"Wang","year":"2022","journal-title":"Microb. Infect."},{"key":"10.1016\/j.heliyon.2023.e16813_bib73","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13104-020-05439-x","article-title":"Identification and characterization of a silent mutation in RNA binding domain of N protein coding gene from SARS-CoV-2","volume":"14","author":"Zolfaghari Emameh","year":"2021","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.heliyon.2023.e16813_bib74","first-page":"1","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib75","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e16813_bib76","series-title":"COVID-19 Vaccines WHO EUL Issued | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)","year":"2022"},{"key":"10.1016\/j.heliyon.2023.e16813_bib77","series-title":"WHO \u2013 COVID19 Vaccine Tracker","year":"2022"},{"key":"10.1016\/j.heliyon.2023.e16813_bib78","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jama.2021.0600","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of pfizer-BioNTech COVID-19 vaccine","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.heliyon.2023.e16813_bib79","article-title":"Editorial: SARS-CoV-2 mRNA vaccines and the possible mechanism of vaccine-induced immune thrombotic thrombocytopenia (VITT)","volume":"27","author":"Parums","year":"2021","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.heliyon.2023.e16813_bib80","article-title":"WHO recommendation Moderna COVID-19 mRNA Vaccine (nucleoside modified)","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib81","series-title":"Overview of Janssen \u2019 S Single-Dose COVID-19 Vaccine, Ad26","first-page":"1","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib82","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The advisory committee on immunization practices' interim recommendation for use of Moderna COVID-19 vaccine \u2014 United States, december 2020","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.heliyon.2023.e16813_bib83","article-title":"Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy","volume":"371","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2023.e16813_bib84","author":"Ndwandwe","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib85","series-title":"Capacity Building | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib86","series-title":"The Sinopharm COVID-19 Vaccine: what You Need to Know","first-page":"1","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib87","first-page":"19","author":"Who","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib88","series-title":"Sinovac Vaccine Age Range","year":"2020"},{"key":"10.1016\/j.heliyon.2023.e16813_bib89","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2023.e16813_bib90","article-title":"Bharat biotech \u2019 s \u2018 COVAXIN TM \u2019 emergency use authorization approval by DCGI-CDSCO , MoH & FW , a significant landmark in India \u2019 s scie ntific discovery , and scientists capability","volume":"3","author":"Welfare","year":"2021","journal-title":"Bharat Biotech"},{"key":"10.1016\/j.heliyon.2023.e16813_bib91","article-title":"Inactivated COVID-19 vaccine BBV152\/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2","volume":"28","author":"Sapkal","year":"2021","journal-title":"J. Trav. Med."},{"key":"10.1016\/j.heliyon.2023.e16813_bib92","series-title":"WHO Recommendation Serum Institute of India Pvt. Ltd. (SIIPL) \u2013 COVID-19 Vaccine (SARS-CoV-2 rS Protein Nanoparticle [Recombinant]) - COVOVAXTM | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control","year":"2022"},{"key":"10.1016\/j.heliyon.2023.e16813_bib93","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"2019 nCoV-302 study group, safety and efficacy of NVX-CoV2373 covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2023.e16813_bib94","year":"2021"},{"key":"10.1016\/j.heliyon.2023.e16813_bib95","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2023.e16813_bib96","first-page":"10","article-title":"Sputnik V vaccine goes global","volume":"250","author":"Lawton","year":"2021","journal-title":"New Sci."},{"key":"10.1016\/j.heliyon.2023.e16813_bib97","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/d41586-021-01813-2","article-title":"Mounting evidence suggests Sputnik COVID vaccine is safe and effective","volume":"595","author":"Nogrady","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2023.e16813_bib98","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41579-020-00462-y","article-title":"Learning from the past: development of safe and effective COVID-19 vaccines","volume":"19","author":"Su","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib99","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/jmv.27487","article-title":"COVID\u201019 vaccinations: the unknowns, challenges, and hopes","volume":"94","author":"Mohamed","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.961198","article-title":"Fast-track development of vaccines for SARS-CoV-2: the shots that saved the world","volume":"13","author":"Chavda","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e16813_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.873596","article-title":"The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: a systematic review and meta-analysis","volume":"10","author":"Rahmani","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.heliyon.2023.e16813_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.00382-20","article-title":"Silico structure-based repositioning of approved drugs for spike glycoprotein S2 domain fusion peptide of SARS-CoV-2: rationale from molecular dynamics and binding free energy calculations","volume":"5","author":"Shekhar","year":"2020","journal-title":"mSystems"},{"key":"10.1016\/j.heliyon.2023.e16813_bib103","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12929-022-00853-8","article-title":"COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection","volume":"29","author":"Chi","year":"2022","journal-title":"J. Biomed. Sci."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023040203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023040203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:34:57Z","timestamp":1790469297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023040203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2405844023040203"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16813","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16813","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e16813"}}